[96a5a0]: / output / allTrials / identified / NCT06603376_identified.json

Download this file

723 lines (723 with data), 31.4 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
{
"info": {
"nct_id": "NCT06603376",
"official_title": "A Randomized, Multicenter, Controlled Study of Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer",
"inclusion_criteria": "* Patients with advanced colorectal adenocarcinoma confirmed by histology or cytology.\n* Patients with BRAFV600E mutation confirmed by tissue or blood testing.\n* Patients who have not received systemic therapy or who have experienced metastasis or recurrence 12 months after completing adjuvant therapy.\n* Patients must have at least one measurable lesion according to RECIST 1.1 criteria.\n* Patients who received local radiotherapy at least 3 weeks before the first drug treatment are allowed to enroll, but lesions evaluated by RECIST should not be within the radiation field.\n* Patients aged ≥18 years and ≤80 years.\n* ECOG performance status of 0-2.\n* Expected survival of ≥12 weeks.\n* Patients must have the ability to understand and voluntarily sign a written informed consent.\n* Women of childbearing potential must have a negative pregnancy test within 7 days prior to the start of treatment. During the study, both the patient and their partner must use contraception.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 80 Years",
"exclusion_criteria": "* Patients who have undergone major surgery or suffered severe trauma within 4 weeks prior to the first dose of the study drug.\n* Patients with hypersensitivity to any component of the study regimen.\n* Patients who are planning to conceive or are already pregnant.\n* Patients with brain metastases who cannot accurately describe their condition.\n* Patients with the following conditions within 6 months prior to the start of the study treatment: myocardial infarction, severe/unstable angina, congestive heart failure greater than NYHA Class 2, uncontrolled arrhythmias, etc.\n* Abnormal laboratory test results:\n* Absolute neutrophil count (ANC) <1,500/mm³;\n* Platelet count <75,000/mm³;\n* Total bilirubin >1.5 times the upper limit of normal (ULN); ALT (alanine aminotransferase) and AST (aspartate aminotransferase) >2.5 times ULN (for patients with liver metastasis >5 times ULN); Creatinine >1.5 times ULN;\n* Patients who have had any cancer other than advanced colorectal cancer within five years prior to the start of the study treatment. Exceptions include cervical carcinoma in situ, cured basal cell carcinoma, and bladder epithelial tumors.\n* Patients with a history of drug abuse, substance abuse, or alcohol dependence.\n* Patients who are legally incapacitated or have limited civil capacity.\n* Any other conditions deemed unsuitable for enrollment by the investigator.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Patients with advanced colorectal adenocarcinoma confirmed by histology or cytology.",
"criterions": [
{
"exact_snippets": "advanced colorectal adenocarcinoma",
"criterion": "colorectal adenocarcinoma",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "advanced"
}
]
},
{
"exact_snippets": "confirmed by histology or cytology",
"criterion": "confirmation method",
"requirements": [
{
"requirement_type": "method",
"expected_value": [
"histology",
"cytology"
]
}
]
}
]
},
{
"line": "* Patients with BRAFV600E mutation confirmed by tissue or blood testing.",
"criterions": [
{
"exact_snippets": "BRAFV600E mutation confirmed by tissue or blood testing",
"criterion": "BRAFV600E mutation",
"requirements": [
{
"requirement_type": "confirmation",
"expected_value": true
}
]
}
]
},
{
"line": "* Patients who have not received systemic therapy or who have experienced metastasis or recurrence 12 months after completing adjuvant therapy.",
"criterions": [
{
"exact_snippets": "Patients who have not received systemic therapy",
"criterion": "systemic therapy",
"requirements": [
{
"requirement_type": "receipt",
"expected_value": false
}
]
},
{
"exact_snippets": "metastasis",
"criterion": "metastasis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "recurrence 12 months after completing adjuvant therapy",
"criterion": "recurrence",
"requirements": [
{
"requirement_type": "timing",
"expected_value": "12 months after completing adjuvant therapy"
}
]
}
]
},
{
"line": "* Patients must have at least one measurable lesion according to RECIST 1.1 criteria.",
"criterions": [
{
"exact_snippets": "at least one measurable lesion according to RECIST 1.1 criteria",
"criterion": "measurable lesion",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "lesion"
}
},
{
"requirement_type": "measurement standard",
"expected_value": "RECIST 1.1"
}
]
}
]
},
{
"line": "* Patients who received local radiotherapy at least 3 weeks before the first drug treatment are allowed to enroll, but lesions evaluated by RECIST should not be within the radiation field.",
"criterions": [
{
"exact_snippets": "Patients who received local radiotherapy at least 3 weeks before the first drug treatment",
"criterion": "local radiotherapy",
"requirements": [
{
"requirement_type": "time since treatment",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "lesions evaluated by RECIST should not be within the radiation field",
"criterion": "lesions evaluated by RECIST",
"requirements": [
{
"requirement_type": "location",
"expected_value": "not within the radiation field"
}
]
}
]
},
{
"line": "* Patients aged ≥18 years and ≤80 years.",
"criterions": [
{
"exact_snippets": "aged ≥18 years and ≤80 years",
"criterion": "age",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 18,
"unit": "years"
},
{
"operator": "<=",
"value": 80,
"unit": "years"
}
]
}
}
]
}
]
},
{
"line": "* ECOG performance status of 0-2.",
"criterions": [
{
"exact_snippets": "ECOG performance status of 0-2",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 2,
"unit": "N/A"
}
]
}
}
]
}
]
},
{
"line": "* Expected survival of ≥12 weeks.",
"criterions": [
{
"exact_snippets": "Expected survival of ≥12 weeks.",
"criterion": "expected survival",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 12,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* Patients must have the ability to understand and voluntarily sign a written informed consent.",
"criterions": [
{
"exact_snippets": "ability to understand",
"criterion": "cognitive ability",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "voluntarily sign a written informed consent",
"criterion": "consent capability",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Women of childbearing potential must have a negative pregnancy test within 7 days prior to the start of treatment. During the study, both the patient and their partner must use contraception.",
"criterions": [
{
"exact_snippets": "Women of childbearing potential",
"criterion": "childbearing potential",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "must have a negative pregnancy test within 7 days prior to the start of treatment",
"criterion": "pregnancy test",
"requirements": [
{
"requirement_type": "result",
"expected_value": "negative"
},
{
"requirement_type": "timing",
"expected_value": "within 7 days prior to the start of treatment"
}
]
},
{
"exact_snippets": "During the study, both the patient and their partner must use contraception",
"criterion": "contraception use",
"requirements": [
{
"requirement_type": "timing",
"expected_value": "during the study"
},
{
"requirement_type": "participants",
"expected_value": [
"patient",
"partner"
]
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
},
{
"line": "Must have maximum age of 80 Years",
"criterions": [
{
"exact_snippets": "maximum age of 80 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 80,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Patients who have undergone major surgery or suffered severe trauma within 4 weeks prior to the first dose of the study drug.",
"criterions": [
{
"exact_snippets": "undergone major surgery",
"criterion": "major surgery",
"requirements": [
{
"requirement_type": "time since event",
"expected_value": {
"operator": "<",
"value": 4,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "suffered severe trauma",
"criterion": "severe trauma",
"requirements": [
{
"requirement_type": "time since event",
"expected_value": {
"operator": "<",
"value": 4,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* Patients with hypersensitivity to any component of the study regimen.",
"criterions": [
{
"exact_snippets": "hypersensitivity to any component of the study regimen",
"criterion": "hypersensitivity",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Patients with brain metastases who cannot accurately describe their condition.",
"criterions": [
{
"exact_snippets": "brain metastases",
"criterion": "brain metastases",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "cannot accurately describe their condition",
"criterion": "ability to describe condition",
"requirements": [
{
"requirement_type": "accuracy",
"expected_value": false
}
]
}
]
},
{
"line": "* Patients with the following conditions within 6 months prior to the start of the study treatment: myocardial infarction, severe/unstable angina, congestive heart failure greater than NYHA Class 2, uncontrolled arrhythmias, etc.",
"criterions": [
{
"exact_snippets": "myocardial infarction",
"criterion": "myocardial infarction",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "severe/unstable angina",
"criterion": "angina",
"requirements": [
{
"requirement_type": "severity",
"expected_value": [
"severe",
"unstable"
]
}
]
},
{
"exact_snippets": "congestive heart failure greater than NYHA Class 2",
"criterion": "congestive heart failure",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": ">",
"value": 2,
"unit": "NYHA Class"
}
}
]
},
{
"exact_snippets": "uncontrolled arrhythmias",
"criterion": "arrhythmias",
"requirements": [
{
"requirement_type": "control",
"expected_value": "uncontrolled"
}
]
}
]
},
{
"line": "* Abnormal laboratory test results:",
"criterions": [
{
"exact_snippets": "Abnormal laboratory test results",
"criterion": "laboratory test results",
"requirements": [
{
"requirement_type": "normality",
"expected_value": false
}
]
}
]
},
{
"line": "* Patients who have had any cancer other than advanced colorectal cancer within five years prior to the start of the study treatment. Exceptions include cervical carcinoma in situ, cured basal cell carcinoma, and bladder epithelial tumors.",
"criterions": [
{
"exact_snippets": "Patients who have had any cancer other than advanced colorectal cancer within five years prior to the start of the study treatment.",
"criterion": "history of cancer",
"requirements": [
{
"requirement_type": "timeframe",
"expected_value": {
"operator": "<=",
"value": 5,
"unit": "years"
}
},
{
"requirement_type": "type",
"expected_value": "any cancer other than advanced colorectal cancer"
}
]
},
{
"exact_snippets": "Exceptions include cervical carcinoma in situ, cured basal cell carcinoma, and bladder epithelial tumors.",
"criterion": "cancer exceptions",
"requirements": [
{
"requirement_type": "type",
"expected_value": [
"cervical carcinoma in situ",
"cured basal cell carcinoma",
"bladder epithelial tumors"
]
}
]
}
]
},
{
"line": "* Patients with a history of drug abuse, substance abuse, or alcohol dependence.",
"criterions": [
{
"exact_snippets": "history of drug abuse",
"criterion": "drug abuse",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "history of ... substance abuse",
"criterion": "substance abuse",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "history of ... alcohol dependence",
"criterion": "alcohol dependence",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
},
{
"line": "* Patients who are legally incapacitated or have limited civil capacity.",
"criterions": [
{
"exact_snippets": "legally incapacitated",
"criterion": "legal capacity",
"requirements": [
{
"requirement_type": "status",
"expected_value": "incapacitated"
}
]
},
{
"exact_snippets": "limited civil capacity",
"criterion": "civil capacity",
"requirements": [
{
"requirement_type": "status",
"expected_value": "limited"
}
]
}
]
},
{
"line": "* Any other conditions deemed unsuitable for enrollment by the investigator.",
"criterions": [
{
"exact_snippets": "Any other conditions deemed unsuitable for enrollment by the investigator.",
"criterion": "conditions deemed unsuitable",
"requirements": [
{
"requirement_type": "determination",
"expected_value": "by the investigator"
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [
{
"line": "* Patients who are planning to conceive or are already pregnant.",
"criterions": [
{
"exact_snippets": "Patients who are planning to conceive",
"criterion": "planning to conceive",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "patients who are ... already pregnant",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Absolute neutrophil count (ANC) &lt;1,500/mm³;",
"criterions": [
{
"exact_snippets": "Absolute neutrophil count (ANC) <1,500/mm³;",
"criterion": "absolute neutrophil count (ANC)",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "<",
"value": 1500,
"unit": "mm³"
}
}
]
}
]
},
{
"line": "* Platelet count &lt;75,000/mm³;",
"criterions": [
{
"exact_snippets": "Platelet count <75,000/mm³;",
"criterion": "platelet count",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "<",
"value": 75000,
"unit": "mm³"
}
}
]
}
]
},
{
"line": "* Total bilirubin &gt;1.5 times the upper limit of normal (ULN); ALT (alanine aminotransferase) and AST (aspartate aminotransferase) &gt;2.5 times ULN (for patients with liver metastasis &gt;5 times ULN); Creatinine &gt;1.5 times ULN;",
"criterions": [
{
"exact_snippets": "Total bilirubin >1.5 times the upper limit of normal (ULN)",
"criterion": "total bilirubin",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 1.5,
"unit": "times ULN"
}
}
]
},
{
"exact_snippets": "ALT (alanine aminotransferase) and AST (aspartate aminotransferase) >2.5 times ULN",
"criterion": "ALT and AST",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 2.5,
"unit": "times ULN"
}
}
]
},
{
"exact_snippets": "(for patients with liver metastasis >5 times ULN)",
"criterion": "ALT and AST for patients with liver metastasis",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 5,
"unit": "times ULN"
}
}
]
},
{
"exact_snippets": "Creatinine >1.5 times ULN",
"criterion": "creatinine",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 1.5,
"unit": "times ULN"
}
}
]
}
]
}
],
"failed_miscellaneous": []
}